Jasper Therapeutics announced that four abstracts on its experimental antibody therapy, briquilimab, have been accepted for presentation at the upcoming EAACI Congress 2025 in Glasgow. The presentations, scheduled for June 14-15, will include both oral and poster sessions and focus on early clinical data from the SPOTLIGHT Phase 1b/2a study, which tests briquilimab in patients with cold urticaria and symptomatic dermographism.
The abstracts cover a range of topics, including the initial results from the SPOTLIGHT trial, briquilimab’s protective effects against allergen-induced dermatitis in mice, disease control in patients with chronic spontaneous urticaria (CSU), and its impact on COPD-like features in asthma models.
Jasper’s clinical data from the 180mg cohort in the SPOTLIGHT study highlight potential benefits for patients with inducible urticarias (CIndU) who have not responded to standard antihistamine treatments. Additionally, updated findings from the Phase 1b/2a CSU trial suggest rapid and meaningful disease control.
The company’s research also extends to preclinical studies exploring briquilimab’s broader use in allergic and inflammatory diseases, such as dermatitis and asthma. By targeting c-Kit (CD117), a receptor essential for mast cell growth and function, briquilimab could offer a new treatment platform addressing several conditions driven by mast cell dysfunction.
Presenting these data at a major allergology conference gives Jasper important exposure to key opinion leaders who shape treatment guidelines and prescribing habits, potentially expanding briquilimab’s future market opportunities.
Related Topics:
